965
Views
9
CrossRef citations to date
0
Altmetric
Research Article

The anticancer effects of biodegradable nanomagnetic dual natural components on the leptin gene expression in lung cancer

, , , &
Pages 1753-1763 | Received 02 Jul 2015, Accepted 24 Sep 2015, Published online: 22 Nov 2015

References

  • Akbarzadeh A, Mikaeili H, Zarghami N, Mohammad R, Barkhordari A, Davaran S. 2012. Preparation and in vitro evaluation of doxorubicin-loaded Fe3O4 magnetic nanoparticles modified with biocompatible copolymers. Int J Nanomed. 7:511.
  • Anganeh MT, Mirakabad FST, Izadi M, Zeighamian V, Badrzadeh F, Salehi R, et al. 2014. The comparison between effects of free curcumin and curcumin loaded PLGA–PEG on telomerase and TRF1 expressions in calu-6 lung cancer cell line. Int J Biosci. 4:134–145.
  • Babu A, Templeton AK, Munshi A, Ramesh R. 2013. Nanoparticle-based drug delivery for therapy of lung cancer: progress and challenges. J Nanomater. 2013:14.
  • Badrzadeh F, Akbarzadeh A, Zarghami N, Yamchi MR, Zeighamian V, Tabatabae FS, et al. 2014. Comparison between effects of free curcumin and curcumin loaded NIPAAm-MAA nanoparticles on telomerase and PinX1 gene expression in lung cancer cells. Asian Pac J Cancer Prev. 15:8931–8936.
  • Badrzadeh F, Rahmati-Yamchi M, Badrzadeh K, Valizadeh A, Zarghami N, Farkhani SM, et al. 2014. Drug delivery and nanodetection in lung cancer. Artif Cells Nanomed Biotechnol. 11:1–17.
  • Chandolu V, Dass CR. 2013. Treatment of lung cancer using nanoparticle drug delivery systems. Curr Drug Discov Technol. 10:170–176.
  • Chang B, Sha X, Guo J, Jiao Y, Wang C, Yang W. 2011. Thermo and pH dual responsive, polymer shell coated, magnetic mesoporous silica nanoparticles for controlled drug release. J Mater Chem. 21:9239–9247.
  • Cirillo D, Rachiglio AM, la Montagna R, Giordano A, Normanno N. 2008. Leptin signaling in breast cancer: an overview. J Cell Biochem. 105:956–964.
  • Clément K, Vaisse C, Lahlou N, Cabrol S, Pelloux V, Cassuto D, et al. 1998. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature. 392:398–401.
  • Danafar H, Davaran S, Rostamizadeh K, Valizadeh H, Hamidi M. 2014. Biodegradable m-PEG/PCL core–shell micelles: preparation and characterization as a sustained release formulation for curcumin. Adv Pharm Bull. 4:501–510.
  • Ebrahimnezhad Z, Zarghami N, Keyhani M, Amirsaadat S, Akbarzadeh A, Rahmati M, et al. 2013. Inhibition of hTERT gene expression by silibinin-loaded PLGA–PEG–Fe3O4 in T47D breast cancer cell line. Bioimpacts 3:67.
  • Feng R, Song Z, Zhai G. 2012. Preparation and in vivo pharmacokinetics of curcumin-loaded PCL–PEG–PCL triblock copolymeric nanoparticles. Int J Nanomed. 7:4089.
  • Jia Y, Yuan M, Yuan H, Huang X, Sui X, Cui X, et al. 2012. Co-encapsulation of magnetic Fe3O4 nanoparticles and doxorubicin into biodegradable PLGA nanocarriers for intratumoral drug delivery. Int J Nanomed. 7:1697.
  • Kliman HJ, Nestler JE, Sermasi E, Sanger JM, Strauss III JF. 1986. Purification, characterization, and in vitro differentiation of cytotrophoblasts from human term placentae. Endocrinology. 118:1567–1582.
  • Lai Q, Sun Y. 2013. Human leptin protein induces proliferation of A549 cells via inhibition of PKR-Like ER kinase and activating transcription factor-6 mediated apoptosis. Yonsei Med J. 54:1407–1415.
  • Li L, Ahmed B, Mehta K, Kurzrock R. 2007. Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer. Mol Cancer Ther. 6:1276–1282.
  • Liptay MJ, Grondin SC, Fry WA, Pozdol C, Carson D, Knop C, et al. 2002. Intraoperative sentinel lymph node mapping in non-small-cell lung cancer improves detection of micrometastases. J Clin Oncol. 20:1984–1988.
  • Moorthi C, Kathiresan K. 2013. Curcumin–piperine/curcumin–quercetin/curcumin–silibinin dual drug-loaded nanoparticulate combination therapy: a novel approach to target and treat multidrug-resistant cancers. J Med Hypotheses Ideas. 7:15–20.
  • Moorthi C, Kumar CS, Kathiresan K. 2014. Synergistic anti-cancer activity of curcumin and bio-enhancers combination against various cancer cell lines. Int J Pharm Pharm Sci. 6:901–903.
  • Mukerjee A, Vishwanatha JK. 2009. Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy. Anticancer Res. 29:3867–3875.
  • Nasiri M, Zarghami N, Koshki KN, Mollazadeh M, Moghaddam MP, Rahmati M. 2013. Curcumin and silibinin inhibit telomerase expression in T47D human breast cancer cells. Asian Pac J Cancer Prev. 14:3449–3453.
  • Nejati-Koshki K, Akbarzadeh A, Pourhasan-Moghadam M, Joo S. 2013. Inhibition of leptin and leptin receptor gene expression by silibinin–curcumin combination. Asian Pac J Cancer Prev. 14:6595–6599.
  • Pillai GR, Srivastava AS, Hassanein TI, Chauhan DP, Carrier E. 2004. Induction of apoptosis in human lung cancer cells by curcumin. Cancer Lett. 208:163–170.
  • Rami A, Zarghami N. 2013. Comparison of inhibitory effect of curcumin nanoparticles and free curcumin in human telomerase reverse transcriptase gene expression in breast cancer. Adv Pharm Bull. 3:127.
  • Salehi R, Hamishehkar H, Eskandani M, Mahkam M, Davaran S. 2014. Development of dual responsive nanocomposite for simultaneous delivery of anticancer drugs. J Drug Target. 22:327–342.
  • Salehi R, Rasouli S, Hamishehkar H. 2015. Smart thermo/pH responsive magnetic nanogels for the simultaneous delivery of doxorubicin and methotrexate. Int J Pharm. 487:274–284.
  • Shen Y, Wang Q, Zhao Q, Zhou J. 2009. Leptin promotes the immune escape of lung cancer by inducing proinflammatory cytokines and resistance to apoptosis. Mol Med Rep. 2:295–299.
  • Siegel R, Ma J, Zou Z, Jemal A. 2014. Cancer statistics, 2014. CA Cancer J Clin. 64:9–29.
  • Singh RP, Deep G, Chittezhath M, Kaur M, Dwyer-Nield LD, Malkinson AM, et al. 2006. Effect of silibinin on the growth and progression of primary lung tumors in mice. J Natl Cancer Inst. 98:846–855.
  • Song C-H, Liao J, Deng Z-H, Zhang J-Y, Xue H, Li Y-M, et al. 2014. Is leptin a predictive factor in patients with lung cancer? Clin Biochem. 47:230–232.
  • Torchilin V. 2009. Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. Eur J Pharm Biopharm. 71:431–444.
  • VanSaun MN. 2013. Molecular pathways: adiponectin and leptin signaling in cancer. Clin Cancer Res. 19:1926–1932.
  • Wu S-H, Hang L-W, Yang J-S, Chen H-Y, Lin H-Y, Chiang J-H, et al. 2010. Curcumin induces apoptosis in human non-small cell lung cancer NCI-H460 cells through ER stress and caspase cascade-and mitochondria-dependent pathways. Anticancer Res. 30:2125–2133.
  • Xiao K, Jiang J, Guan C, Dong C, Wang G, Bai L, et al. 2013. Curcumin induces autophagy via activating the AMPK signaling pathway in lung adenocarcinoma cells. J Pharmacol Sci. 123:102–109.
  • Yallapu MM, Ebeling MC, Khan S, Sundram V, Chauhan N, Gupta BK, et al. 2013. Novel curcumin-loaded magnetic nanoparticles for pancreatic cancer treatment. Mol Cancer Ther. 12:1471–1480.
  • Yang H-W, Hua M-Y, Liu H-L, Huang C-Y, Wei K-C. 2012. Potential of magnetic nanoparticles for targeted drug delivery. Nanotechnol Sci Appl. 5:73.
  • YesilbagáTonga G. 2013. Characterization of surface ligands on functionalized magnetic nanoparticles using laser desorption/ionization mass spectrometry (LDI-MS). Nanoscale. 5:5063–5066.
  • Yin H, Zhang H, Liu B. 2013. Superior anticancer efficacy of curcumin-loaded nanoparticles against lung cancer. Acta Biochim Biophys Sin. 45:634–640.
  • Zhang J, Misra R. 2007. Magnetic drug-targeting carrier encapsulated with thermosensitive smart polymer: core–shell nanoparticle carrier and drug release response. Acta Biomater. 3:838–850.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.